Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo
Arrowhead PharmaceuticalsArrowhead Pharmaceuticals(US:ARWR) Businesswire·2026-03-28 22:30

公司核心产品进展 - Arrowhead Pharmaceuticals公司宣布了其研究性药物plozasiran为期两年的开放标签扩展研究的长期疗效和安全性数据 [1] - 该数据支持plozasiran有潜力成为治疗多种高甘油三酯血症患者的治疗解决方案 [1] - 数据由贝勒医学院教授、贝勒大学德州心脏研究所成员Christie M. Ballantyne博士展示 [1] 行业研发动态 - 生物制药行业持续关注针对高甘油三酯血症等代谢性疾病的新型疗法开发 [1]

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo - Reportify